Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

References

• DelgermaaVTakahashiKParkEKLeGVHaraTSorahanTGlobal mesothelioma deaths reported to the World Health Organization between 1994 and 2008Bull World Health Organ20118910716724724A724C22084509
   PubMed Web of Science ®Google Scholar
• KaufmanAJFloresRMSurgical treatment of malignant pleural mesotheliomaCurr Treat Options Oncol201112220121621465419
   PubMedGoogle Scholar
• EttingerDSWoodDEAkerleyWNCCN Guidelines Insights: malignant pleural mesothelioma, Version 3. 2016J Natl Compr Canc Netw201614782583627407123
   PubMed Web of Science ®Google Scholar
• FloresRMRiedelEDoningtonJSFrequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) populationJ Thorac Oncol20105101649165420871264
   PubMed Web of Science ®Google Scholar
• FloresRMZakowskiMVenkatramanEPrognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral centerJ Thorac Oncol200721095796517909360
   PubMed Web of Science ®Google Scholar
• VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
   PubMed Web of Science ®Google Scholar
• KatirtzoglouNGkiozosIMakriliaNCarboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II studyClin Lung Cancer2010111303520085865
   PubMed Web of Science ®Google Scholar
• CeresoliGLZucaliPAFavarettoAGPhase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaJ Clin Oncol20062491443144816549838
   PubMed Web of Science ®Google Scholar
• CastagnetoBBottaMAitiniEPhase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)Ann Oncol200819237037318156144
   PubMed Web of Science ®Google Scholar
• ShibuyaMVascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapiesGenes Cancer20112121097110522866201
   PubMedGoogle Scholar
• BranchaudRMMacDonaldJLKaneABInduction of angiogenesis by intraperitoneal injection of asbestos fibersFASEB J198936174717522467835
   PubMedGoogle Scholar
• Kumar-SinghSWeylerJMartinMJVermeulenPBVan MarckEAngiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expressionJ Pathol19991891727810451491
   PubMed Web of Science ®Google Scholar
• EdwardsJGCoxGAndiAAngiogenesis is an independent prognostic factor in malignant mesotheliomaBr J Cancer200185686386811556838
   PubMed Web of Science ®Google Scholar
• OhtaYShridharVBrightRKVEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumoursBr J Cancer1999811546110487612
   PubMed Web of Science ®Google Scholar
• SoiniYPuhakkaAKahlosKEndothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1Histopathology200139217918611493335
   PubMedGoogle Scholar
• Al-HuseinBAbdallaMTrepteMDeremerDLSomanathPRAntiangiogenic therapy for cancer: an updatePharmacotherapy201232121095111123208836
   PubMed Web of Science ®Google Scholar
• GordonMSMargolinKTalpazMPhase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerJ Clin Oncol200119384385011157038
   PubMed Web of Science ®Google Scholar
• JahanTGuLKratzkeRVatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)Lung Cancer201276339339622197613
   PubMed Web of Science ®Google Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200422112184219115169807
   PubMed Web of Science ®Google Scholar
• HurwitzHISaltzLBVan CutsemEVenous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studiesJ Clin Oncol201129131757176421422411
   PubMed Web of Science ®Google Scholar
• CassidyJSaltzLBGiantonioBJKabbinavarFFHurwitzHIRohrUPEffect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJ Cancer Res Clin Oncol2010136573774319904559
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• JackmanDMKindlerHLYeapBYErlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaCancer2008113480881418543326
   PubMed Web of Science ®Google Scholar
• KindlerHLKarrisonTGGandaraDRMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesotheliomaJ Clin Oncol201230202509251522665541
   PubMed Web of Science ®Google Scholar
• ShakedYHenkeERoodhartJMRapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for anti-angiogenic drugs as chemosensitizing agentsCancer Cell200814326327318772115
   PubMed Web of Science ®Google Scholar
• CeresoliGLZucaliPAMencoboniMPhase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesotheliomaBr J Cancer2013109355255823860535
   PubMed Web of Science ®Google Scholar
• DowellJEDunphyFRTaubRNA multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesotheliomaLung Cancer201277356757122770372
   PubMed Web of Science ®Google Scholar
• ZalcmanGMazieresJMargeryJBevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialLancet2016387100261405141426719230
   PubMed Web of Science ®Google Scholar
• NowakAKMillwardMJCreaneyJA phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesotheliomaJ Thorac Oncol2012791449145622895142
   PubMed Web of Science ®Google Scholar
• CamidgeDRBlaisNJonkerDJSunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesotheliomaCancer Chemother Pharmacol201371230731923108697
   PubMed Web of Science ®Google Scholar
• DubeySJannePAKrugLA phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307J Thorac Oncol20105101655166120736856
   PubMed Web of Science ®Google Scholar
• PapaSPopatSShahRPhase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapyJ Thorac Oncol20138678378723571475
   PubMed Web of Science ®Google Scholar
• GarlandLLChanskyKWozniakAJPhase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509J Thorac Oncol20116111938194521964533
   PubMed Web of Science ®Google Scholar
• CampbellNPKunnavakkamRLeighlNCediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II ConsortiumLung Cancer2012781768022831987
   PubMed Web of Science ®Google Scholar
• ScagliottiGVGaafarRMNowakAKLumemeso: a double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N vs placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM)J Clin Oncol201634
   PubMedGoogle Scholar
• GrossoFNintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso TrialPaper presented at: International Association for the Study of Lung Cancer – World Conference on Lung CancerJuly 12, 2016Vienna, Austria
   Google Scholar
• KindlerHLVogelzangNJChienKSU5416 in Malignant Mesothelioma: a University of Chicago Phase II Consortium Study [abstract]Proceedings of ASCO, 200120 341:a1359
   Google Scholar
• MolinaJPhase II Study of GW786034 in Patients With Malignant Pleural MesotheliomaClinicalTrials.gov [Internet]Bethesda (MD)National Library of Medicine (US)2000 Available from: https://clinicaltrials.gov/ct2/show/study/NCT00459862Accessed November 23, 2016
   Google Scholar
• BuikhuisenWAScharpfeneckerMGriffioenAWKorseCMvan TinterenHBaasPA randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomesJ Thorac Oncol201611575876826845191
   PubMed Web of Science ®Google Scholar
• PortaCGiglionePLiguigliWPaglinoCDovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activityFuture Oncol20151113950
   PubMed Web of Science ®Google Scholar
• LaurieSA Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy2015 Available from: https://clinicaltrials.gov/ct2/show/record/NCT01769547Accessed November 26, 2016
   Google Scholar
• KaurSChangTSinghSPCD47 signaling regulates the immunosuppressive activity of VEGF in T cellsJ Immunol201419383914392425200950
   PubMedGoogle Scholar